Heart Failure – Current Treatment – Detailed, Expanded Analysis: Chronic Heart Failure – Reduced Ejection Fraction – Treatment Algorithms – Claims Data Analysis (US)
Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF) is well established with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta-blockers, and loop diuretics are typically used in the first-line treatment of HFrEF patients. Given the heavily genericized nature of the market, branded agents, such as Novartis’s Entresto and Amgen’s Corlanor, have had difficulty establishing a foothold; nevertheless, the use of Entresto has been steadily growing since its launch in 2015. This HFrEF Treatment Algorithm report offers insight into the U.S. prescribing patterns in this CHF subpopulation.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
- How have Entresto and Corlanor been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFrEF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Merck, Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, BiDil, Corlanor, Entresto
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Chronic Heart Failure Reduced Ejection Fraction US March 2022
- Treatment Algorithms CDA Chronic Heart Failure Reduced Ejection Fraction US 2022 Dashboard
Dwaipayan Chatterjee, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports focusing on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.